While Lupin has delivered impressive headline growth in recent quarters (for example, Q2 FY26 revenue jumped ~24.2 % YoY and PAT rose ~73%

First, Lupin’s business model dependency on the U.S. generics market — which accounted for ~40% of revenue in FY26 — poses vulnerability to regulatory risk, price erosion and intense competition. With major filings still in progress, manufacturing compliance remains a structural overhang, as evidenced by past FDA inspections and remediation needs. Second, despite margin improvements, the company is still exposed to input cost pressures, foreign-exchange headwinds, and unpredictable pricing in generics, which could compress profitability if product mix turns less favourable. Third, Lupin’s growth over the last five years has not been spectacular (~8% revenue CAGR) despite the strong recent uptick. That gap raises questions on consistency and sustainability of the current run. Fourth, valuation appears fairly elevated for a business with embedded cyclicality: the stock trades at ~4.7× book value and has modest dividend yield (~0.6%) despite heavy reliance on generics volume and margin improvement. Finally, the path from a generics factory to a value-added specialty/biologics player is long and uncertain — Lupin’s R&D spends (~7–8% of sales) are sizeable but convert to approvals and revenue on a multi-year lag, meaning execution risk is material. In short, while Lupin shows signs of revival, the company remains exposed to regulatory, pricing, input cost and execution risks. For long-term investors who prioritise consistency, margin durability, and clarity of growth trajectory, Lupin may warrant a cautious view rather than outright bullish conviction.